Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemlidy for RRMS Symptoms and Neuroprotection
NCT04880577Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenofovir alafenamide in multiple sclerosis (MS), fatigue, sponsored by Massachusetts General Hospital. Planned start Sep 2022; status: withdrawn.
02
Drugs
tenofovir alafenamide
03
Conditions
multiple sclerosis (MS)fatigue
Beyond the preview
Go deeper on NCT04880577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880577.